References
- Barthel BL, Zhang Z, Rudnicki DL, et al. (2009). Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine. J Med Chem 52:7678–88.
- Chuah LO, Yeap SK, Ho WY, et al. (2012). In vitro and in vivo toxicity of garcinia or hydroxycitric acid: a review. Evid Based Complement Alternat Med 2012:197920.
- Dettbarn WD, Yang ZP, Milatovic D. (1999). Different role of carboxylesterases in toxicity and tolerance to paraoxon and DFP. Chem Biol Interact 119–120:445–54.
- Hyatt JL, Tsurkan L, Wierdl M, et al. (2006). Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity. Mol Cancer Ther 5:2281–8.
- Kasibhatla S, Jessen KA, Maliartchouk S, et al. (2005). A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 102:12095–100.
- Li X, Liu S, Huang H, et al. (2013). Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. Cell Rep 3:211–22.
- Li C, Lu N, Qi Q, et al. (2011). Gambogic acid inhibits tumor cell adhesion by suppressing integrin beta1 and membrane lipid rafts-associated integrin signaling pathway. Biochem Pharmacol 82:1873–83.
- Liu W, Ning R, Chen R-N, et al. (2015a). Gambogic acid suppresses cytochrome P450 3A4 by downregulating pregnane X receptor and up-regulating DEC1 in human hepatoma HepG2 cells. Toxicol Res 4:1059–71.
- Liu W, Ning R, Chen RN, et al. (2015b). Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells. Mol Carcinog. [Epub ahead of print]. doi:10.1002/mc.22293.
- Mao Z, Li Y, Peng Y, et al. (2011). Lipopolysaccharide down-regulates carbolesterases 1 and 2 and reduces hydrolysis activity in vitro and in vivo via p38MAPK-NF-κB pathway. Toxicol Lett 201:213–20.
- Quiroga AD, Lehner R. (2011). Role of endoplasmic reticulum neutral lipid hydrolases. Trends Endocrinol Metab 22:218–25.
- Sanghani SP, Sanghani PC, Schiel MA, Bosron WF. (2009). Human carboxylesterases: an update on CES1, CES2 and CES3. Protein Pept Lett 16:1207–14.
- Satoh T, Hosokawa M. (2006). Structure, function and regulation of carboxylesterases. Chem Biol Interact 162:195–211.
- Savi P, Pereillo JM, Uzabiaga MF, et al. (2000). Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891–6.
- Shi D, Yang D, Prinssen EP, et al. (2011). Surge in expression of carboxylesterase 1 during the post-neonatal stage enables a rapid gain of the capacity to activate the anti-influenza prodrug oseltamivir. J Infect Dis 203:937–42.
- Shi D, Yang J, Yang D, Yan B. (2008). Dexamethasone suppresses the expression of multiple rat carboxylesterases through transcriptional repression: evidence for an involvement of the glucocorticoid receptor. Toxicology 254:97–105.
- Tang M, Mukundan M, Yang J, et al. (2006). Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467–76.
- Thomsen R, Rasmussen HB, Linnet K. (2014). In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug Metab Dispos 42:126–33.
- Wang LH, Li Y, Yang SN, et al. (2014a). Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-kappaB and MAPK/HO-1 signalling. Br J Cancer 110:341–52.
- Wang J, Liu W, Zhao Q, et al. (2009). Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 256:135–40.
- Wang LH, Yang JY, Yang SN, et al. (2014b). Suppression of NF-kappaB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin-induced apoptosis in lung cancer. Curr Cancer Drug Targets 14:91–103.
- Wu MH, Yan B, Humerickhouse R, Dolan ME. (2002). Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clin Cancer Res 8:2696–700.
- Xiao D, Chen YT, Yang D, Yan B. (2012). Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation. Biochem Pharmacol 84:232–9.
- Xiao D, Shi D, Yang D, et al. (2013). Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs. Biochem Pharmacol 85:439–47.
- Yang D, Pearce RE, Wang X, et al. (2009). Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol 77:238–47.
- Yang J, Shi D, Yang D, et al. (2007). Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol 72:686–94.
- Yang D, Yang J, Shi D, et al. (2012). Hypolipidemic agent Z-guggulsterone: metabolism interplays with induction of carboxylesterase and bile salt export pump. J Lipid Res 53:529–39.
- Zhang HZ, Kasibhatla S, Wang Y, et al. (2004). Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 12:309–17.
- Zhao W, You CC, Zhuang JP, et al. (2013). Viability inhibition effect of gambogic acid combined with cisplatin on osteosarcoma cells via mitochondria-independent apoptotic pathway. Mol Cell Biochem 382:243–52.
- Zou Z, Xie L, Wei J, et al. (2012a). Synergistic anti-proliferative effects of gambogic acid with docetaxel in gastrointestinal cancer cell lines. BMC Complement Altern Med 12:58.
- Zou ZY, Wei J, Li XL, et al. (2012b). Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells. Cancer Biother Radiopharm 27:299–306.